Get started
Author

Johnny Y. Nagasawa

Observed names: J Nagasawa, Johnny Nagasawa, Johnny Y Nagasawa
OpenAlex ID: A5021286275
Discovery and SAR of 5-(3-Chlorophenylamino)benzo[c][2,6]naphthyridine-8-carboxylic Acid (CX-4945), the First Clinical Stage Inhibitor of Protein Kinase CK2 for the Treatment of Cancer
2010 · Fabrice Pierre, Peter C. Chua, et al. · Journal of Medicinal Chemistry · 306
Identification of GDC-0810 (ARN-810), an Orally Bioavailable Selective Estrogen Receptor Degrader (SERD) that Demonstrates Robust Activity in Tamoxifen-Resistant Breast Cancer Xenografts
2015 · Andiliy Lai, Mehmet Kahraman, et al. · Journal of Medicinal Chemistry · 261
Discovery of CX-5461, the First Direct and Selective Inhibitor of RNA Polymerase I, for Cancer Therapeutics
2012 · Mustapha Haddach, Michael K. Schwaebe, et al. · ACS Medicinal Chemistry Letters · 170
Pre-clinical characterization of CX-4945, a potent and selective small molecule inhibitor of CK2 for the treatment of cancer
2011 · Fabrice Pierre, Peter C. Chua, et al. · Molecular and Cellular Biochemistry · 155
The selective estrogen receptor downregulator GDC-0810 is efficacious in diverse models of ER+ breast cancer
2016 · James D Joseph, Beatrice Darimont, et al. · eLife · 126
Maximizing ER-α Degradation Maximizes Activity in a Tamoxifen-Resistant Breast Cancer Model: Identification of GDC-0927
2018 · Mehmet Kahraman, Steven P. Govek, et al. · ACS Medicinal Chemistry Letters · 81
Optimization of an indazole series of selective estrogen receptor degraders: Tumor regression in a tamoxifen-resistant breast cancer xenograft
2015 · Steven P. Govek, Johnny Y. Nagasawa, et al. · Bioorganic & Medicinal Chemistry Letters · 50
Identification of an Orally Bioavailable Chromene-Based Selective Estrogen Receptor Degrader (SERD) That Demonstrates Robust Activity in a Model of Tamoxifen-Resistant Breast Cancer
2018 · Johnny Nagasawa, Steven Govek, et al. · Journal of Medicinal Chemistry · 44
6-Benzylamino 4-oxo-1,4-dihydro-1,8-naphthyridines and 4-oxo-1,4-dihydroquinolines as HIV integrase inhibitors
2010 · Johnny Y. Nagasawa, Jenny Song, et al. · Bioorganic & Medicinal Chemistry Letters · 27
The design and synthesis of potent and cell-active allosteric dual Akt 1 and 2 inhibitors devoid of hERG activity
2008 · Tony Siu, Yiwei Li, et al. · Bioorganic & Medicinal Chemistry Letters · 19
Cyclohexenyl- and dehydropiperidinyl-alkynyl pyridines as potent metabotropic glutamate subtype 5 (mGlu5) receptor antagonists
2005 · Peter C. Chua, Johnny Y. Nagasawa, et al. · Bioorganic & Medicinal Chemistry Letters · 15
Pyrimidine methyl anilines: selective potentiators for the metabotropic glutamate 2 receptor
2004 · Essa Hu, Peter C. Chua, et al. · Bioorganic & Medicinal Chemistry Letters · 14
Selective estrogen receptor degraders with novel structural motifs induce regression in a tamoxifen-resistant breast cancer xenograft
2018 · Steven P. Govek, Celine Bonnefous, et al. · Bioorganic & Medicinal Chemistry Letters · 10
A novel and efficient synthesis of 3-carboxy-4-oxo-1,8-naphthyridines using magnesium chloride
2008 · Peter C. Chua, Johnny Y. Nagasawa, et al. · Tetrahedron Letters · 10
Correction: The selective estrogen receptor downregulator GDC-0810 is efficacious in diverse models of ER+ breast cancer
2019 · James D Joseph, Beatrice Darimont, et al. · eLife · 7
Author response: The selective estrogen receptor downregulator GDC-0810 is efficacious in diverse models of ER+ breast cancer
2016 · James D Joseph, Beatrice Darimont, et al. · eLife · 5
Facile and efficient generation of quinolone amides from esters using aluminum chloride
2011 · Michael K. Schwaebe, David M. Ryckman, et al. · Tetrahedron Letters · 5
Abstract 1648: Discovery and evolution of orally bioavailable selective estrogen receptor degraders for ER+ breast cancer: From GDC-0810 to GDC-0927
2018 · Mehmet Kahraman, Steven P. Govek, et al. · Cancer Research · 3
P153 Met642, an Oral Fxr Agonist, Improves Colitis Induced by Adoptive T-cell Transfer
2020 · Xueqing Liu, Robert O'Connell, et al. · Gastroenterology · 1
Abstract 4757: A novel class of selective estrogen receptors degraders regresses tumors in pre-clinical models of endocrine-resistant breast cancer
2014 · James D. Joseph, Beatrice Darimont, et al. · Cancer Research · 1
CX-5461 selectively inhibits the SL1 Component of RNA Polymerase I in the ribosome biogenesis pathway and gives potent antitumor activity in models of cancer
2008 · Jeffery Whitten, Denis Drygin, et al. · Cancer Research · 1
767 Activation of Fxr Suppresses Tnfa and Il-6 Signaling Pathways and Improves Colitis in Two Chronic Mouse Models of Ibd
2020 · Xueqing Liu, Robert O'Connell, et al. · Gastroenterology
P153 Met642, an Oral Fxr Agonist, Improves Colitis Induced by Adoptive T-cell Transfer
2020 · Xueqing Liu, Robert O’Connell, et al. · Inflammatory Bowel Diseases
Sa1747 – Fxr Agonists with Sustained Activity Exhibit Efficacy Comparable to Anti-Il-12P40 in Treating Colitis Induced by Adoptive T-Cell Transfer
2019 · Xueqing Liu, Harry Dedman, et al. · Gastroenterology
Sa1737 – Fxr Agonist M480, Exhibits Efficacy in Multiple Models of Inflammatory Bowel Disease (IBD) by Increasing Expression of Anti-Microbial Genes and Reducing Inflammatory Cytokine Expression in the Gut
2019 · Xueqing Liu, Harry Dedman, et al. · Gastroenterology
Works count: 34
Citation count: 1,311
H-index: 12
I10-index: 14
Year
Topic
Type